v3.26.1
Balance Sheet Details
3 Months Ended
Mar. 31, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Balance Sheet Details

5. Balance Sheet Details

 

Inventories

 

Inventories consist of the following (in thousands):

 

   March 31, 2026   December 31, 2025 
Raw materials  $171   $206 
Work in process   1,265    301 
Finished goods   454    622 
Total  $1,890   $1,129 

 

 

Prepaid and Other Current Assets

 

Prepaid and other current assets consist of the following (in thousands):

 

   March 31, 2026   December 31, 2025 
Insurance  $161   $436 
Prescription Drug User Fee Act (PDUFA) fees   442    - 
Receivable from Pharma 1   188    377 
Outside service retainers   26    98 
Short-term deposits   129    131 
Other   281    55 
Total  $1,227   $1,097 

 

Property and Equipment, Net

 

Property and equipment, net, consists of the following (in thousands):

 

   Useful Life  March 31, 2026   December 31, 2025 
Research equipment  5 years  $96   $96 
Computer equipment and software  3 years   37    36 
Construction in-process  -   402    402 
Property and equipment, gross      535    534 
Less: accumulated depreciation      (119)   (116)
Total, net     $416   $418 

 

Depreciation expense for property and equipment was immaterial in each of the three months ended March 31, 2026 and 2025, respectively.

 

Intangible Asset, Net

 

Intangible asset, net, consists of the following (in thousands):

 

   Useful Life  March 31, 2026   December 31, 2025 
Intellectual property  16 years  $1,971   $5,466 
Less: accumulated amortization      (1,193)   (1,118)
Total, net     $778   $4,348 

 

The intangible asset relates entirely to the asset acquired with the SOLOSEC asset acquisition and as described further in Note 7 – Commitments and Contingencies, the useful life is based on the SOLOSEC IP patent expiration. Amortization expense was $0.1 million and $0.2 million in the three months ended March 31, 2026 and 2025, respectively. Amortization expense is expected to be immaterial for the remainder of 2026 and approximately $0.1 million in each subsequent year until the intangible asset is fully amortized, which will be in approximately 14.2 years. As described in Note 2 – Summary of Significant Accounting Policies, the intangible asset value is adjusted at each reporting date in conjunction with the mark-to-market adjustment of the contingent liabilities, which could impact the expected amortization. The intangible asset fair value was reduced by $3.5 million and $2.9 million in the three months ended March 31, 2026 and 2025, respectively.

 

 

Accrued Expenses

 

Accrued expenses consist of the following (in thousands):

 

   March 31, 2026   December 31, 2025 
Accrued royalty  $27   $28 
Accrued compensation for non-employee directors   594    653 
Other   584    611 
Total  $1,205   $1,292 

 

Other current liabilities

 

Other current liabilities consist of the following (in thousands):

 

   March 31, 2026   December 31, 2025 
Variable consideration related to net revenue  $9,757   $11,226 
Liability for loss on purchase commitment   -    304 
Deferred revenue   402    402 
Other   72    84 
Total  $10,231   $12,016